Cognition Therapeutics, Inc. (CGTX)
- Previous Close
1.9500 - Open
1.9300 - Bid 1.9000 x 100
- Ask 1.9900 x 100
- Day's Range
1.8700 - 1.9700 - 52 Week Range
0.9000 - 3.4900 - Volume
55,056 - Avg. Volume
200,306 - Market Cap (intraday)
76.05M - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8600 - Earnings Date May 4, 2024 - May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.67
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
www.cogrx.comRecent News: CGTX
Performance Overview: CGTX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CGTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CGTX
Valuation Measures
Market Cap
76.05M
Enterprise Value
47.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.11
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.86
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-74.08%
Return on Equity (ttm)
-79.69%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-25.79M
Diluted EPS (ttm)
-0.8600
Balance Sheet and Cash Flow
Total Cash (mrq)
29.92M
Total Debt/Equity (mrq)
5.06%
Levered Free Cash Flow (ttm)
-23.04M